
zzso zzso at levels zzso zzso enhances chemotherapy in zzso Yet the approved oral dose of 400 zzso zzso achieves this level in zzso We developed an intermittent oral zzso schedule of V to increase serum zzso We combined V with the zzso dependent zzso inhibitor zzso zzso which increases zzso zzso 

One week before combination treatment, V alone was given daily for zzso zzso zzso Then V was given on zzso and zzso and F on zzso and zzso every zzso Due to zzso this was modified to V on zzso and zzso and F on zzso and zzso every zzso zzso and zzso F schedules were zzso 

34 patients were zzso On the zzso schedule, the maximum tolerated dose zzso was V 600 zzso and F 60 zzso zzso On the zzso schedule, the zzso was V 800 zzso and F 30 zzso over 30 zzso and 30 zzso over 4 zzso V zzso at the 800 zzso dose was zzso zzso zzso zzso V zzso zzso zzso zzso was achieved in zzso of patients at the zzso F increased the zzso of V by zzso zzso zzso zzso F zzso of zzso 2 zzso was achieved in zzso of zzso 8 patients had stable disease for on average zzso m zzso zzso zzso 

zzso high dose oral V in combination with F is feasible and achieves target serum levels zzso zzso V zzso higher than previously reported with oral dosing were zzso 

